Saturday 17 October 2026
Export JBIO’s income statement to Excel — free account
Jade Biosciences, Inc.
JBIO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 11.6% and free cash flow fell 115.1%, each against the same quarter a year earlier.
13.49
0.27
−1.96%
Follow JBIO
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 309.05 | 270.90 | 329.35 | 43.75 | 6.57 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 1,030.05 | 1,077.65 | 1,035.30 | 1,134.53 | 100.10 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 8 | 16 | 43 | 51 | 4 | 55 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (3) | (10) | (23) | (51) | (75) | (47) | (127) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (3) | (10) | (23) | (52) | (76) | (47) | (127) | |||||
| Depreciation | — | — | — | — | 0 | 0 | (1) | (3) | (2) | (1) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (484.82) | (1,393.50) | (65.61) | (73.68) | (100.70) | (14.89) | (3.19) | |||||
| Cash flow | — | — | — | (403.04) | (1,138.99) | (78.19) | (56.09) | (75.65) | (7.17) | (3.02) | |||||
| Capex | — | — | — | 0.00 | 0.00 | (0.52) | (0.28) | (0.19) | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | (403.04) | (1,138.99) | (78.71) | (56.37) | (75.84) | (7.17) | (3.03) | |||||
| Book value | — | — | — | (527.97) | (1,933.91) | 492.06 | 181.71 | 145.84 | (14.83) | 10.60 | |||||
| Shares, m | — | — | — | 0 | 0 | 0 | 1 | 1 | 3 | 31 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (8) | (27) | (39) | (57) | (23) | (95) | ||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | — | 0 | |||||
| Free cash flow | — | — | — | (3) | (8) | (28) | (39) | (57) | (23) | (95) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 3 | 3 | 172 | 124 | 107 | 58 | 332 | ||||
| Total debt | — | — | — | 3 | — | 0 | 1 | — | 108 | — | |||||
| Net debt | — | — | — | (1) | (5) | (167) | (129) | (122) | 38 | (336) | |||||
| Shareholders’ equity | — | — | — | (4) | (13) | 172 | 127 | 109 | (47) | 333 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (189.53) | (233.59) | (25.50) | (33.16) | (57.49) | (46.93) | (47.39) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (265.23) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 39.21 | 113.16 | (28.87) | (34.44) | (63.95) | (149.96) | (70.09) | |||||
Negative figures in brackets.
Charts ten years each
Jade Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics, Inc. | $901.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| AKTS Aktis Oncology, Inc. | $890.5M | — (loss-making) | — (loss-making) | — | n/m | −12.77% (below 0%: shrinking) | 100.00% | (853.99%) | Compare |
| ANRO Alto Neuroscience, Inc. | $887.7M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| RIGL Rigel Pharmaceuticals, Inc. | $882.6M | 2.6× | 7.9× | −22.60% (below 0%: shrinking) | −72.07% (below 0%: shrinking) | −229.99% (below 0%: shrinking) | 89.17% | 29.95% | Compare |
| JBIO Jade Biosciences, Inc. | $875.1M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | |
| MLTX MoonLake Immunotherapeutics | $873.2M | — (loss-making) | — | — | n/m | −1.89% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $863.4M | — (loss-making) | — (loss-making) | −61.33% (below 0%: shrinking) | n/m | −34.11% (below 0%: shrinking) | 100.00% | (547.84%) | Compare |
| KURA Kura Oncology, Inc. | $862.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| ALMS Alumis Inc. | $842.4M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | Compare |
| Median of peers | $877.9M | — | — | −30.13% | — | −23.44% | 100.00% | (174.88%) |
Jade Biosciences, Inc. (JBIO) key facts
- Jade Biosciences, Inc. (JBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, JBIO traded at $13.49, a market capitalization of $875.1 million.
- Return on equity was −70.1% and debt-to-equity 0.00.